An attempt in Nevada to cap insulin prices for people with diabetes and their insurance companies is being abandoned over questions of the proposal's legality.
An unlikely coalition in Nevada is trying to force pharmaceutical drugmakers to refund insurance companies and diabetics if insulin prices surpass inflation.
Executive director of the California Center for Public Health Advocacy joins Insight to discuss the health implications of diabetes as well as policy recommendations.